{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:02:22Z","timestamp":1770418942934,"version":"3.49.0"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Background and Aim:<\/jats:title>\n<jats:p>Basal insulin combined oral therapy consisting of insulin and\noral anti-diabetic drugs (OADs) is recommended for type 2 diabetes uncontrolled on OADs. There\nis a lack of clear evidence and recommendations on the combined use of basal insulin analogues to\nmore than one OADs (glimepiride plus metformin) in effective control of glycemic parameters and\nits safety in terms of reduced hypoglycemic events, weight gain and cardiovascular risk. In this\ncontext, a group of clinical experts discussed the utility of basal insulin combined oral therapy with\nmetformin and glimepiride in the current era.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The clinical experts discussed and provided their inputs virtually. The expert panel included\nclinical experts comprising endocrinologists and diabetologists from India and Nepal.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The panel thoroughly reviewed existing literature on the subject and proposed clinical evidence\nand practice-based guidelines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These current clinical practice guidelines highlight the efficacy and safety of basal insulin\ncombination therapy with various available basal insulins including neutral protamine hagedorn,\ndetemir, glargine and degludec in addition to metformin and glimepiride therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399819666230109104300","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T05:45:03Z","timestamp":1673329503000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Evidence and Practice-Based Guidelines on the Utility of Basal\nInsulin Combined Oral Therapy (Metformin and Glimepiride) in the\nCurrent Era"],"prefix":"10.2174","volume":"19","author":[{"given":"Abhishek","family":"Shrivastava","sequence":"first","affiliation":[{"name":"R&amp;R Hormone Clinic, Jabalpur, Madhya Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[{"name":"Jothydev's Diabetes Research Centre, Konkalam Road,\nMudavanmugal, Trivandrum, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[{"name":"Dr. Mohan\u2019s Diabetes Specialities Centre and Madras Diabetes Research\nFoundation, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[{"name":"Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Norvic International\nHospital and Medical College, and Hospital for Advanced Medicine and Surgery, Maharajganj, Kathmandu, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Department of Medicine, American College of Physicians, BBD University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brij Mohan","family":"Makkar","sequence":"additional","affiliation":[{"name":"Dr. Makkar\u2019s Diabetes &amp;\nObesity Centre, Paschim Vihar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirtikumar D.","family":"Modi","sequence":"additional","affiliation":[{"name":"Care Hospital, Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Kumar  Das","sequence":"additional","affiliation":[{"name":"Pondicherry Institute\nof Medical Sciences, Puducherry, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"172625","DOI":"10.1016\/j.ejphar.2019.172625","volume":"862","author":"Khursheed R.","year":"2019","unstructured":"Khursheed R.; Singh S.K.; Wadhwa S.; Treatment strategies against diabetes: Success so far and challenges ahead. Eur J Pharmacol 2019,862,172625","journal-title":"Eur J Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e00231","DOI":"10.1002\/edm2.231","volume":"4","author":"Das A.K.","year":"2021","unstructured":"Das A.K.; Mithal A.; Joshi S.; Baseline characteristics of participants in the LANDMARC trial: A 3\u2010year, pan \u2010India, prospective, longitudinal study to assess management and real\u2010world outcomes of diabetes mellitus. Endocrinol Diabetes Metab 2021,4(3),e00231","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref=3","first-page":"41","volume":"37","author":"Suzuki D.","year":"2012","unstructured":"Suzuki D.; Umezono T.; Miyauchi M.; Effectiveness of Basal-Supported Oral Therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes. Tokai J Exp Clin Med 2012,37(2),41-46","journal-title":"Tokai J Exp Clin Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12902-015-0051-0","volume":"15","author":"Danne T.","year":"2015","unstructured":"Danne T.; Bluhmki T.; Seufert J.; Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord 2015,15(1),54","journal-title":"BMC Endocr Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JMDH.S64084","volume":"7","author":"Sorli C.","year":"2014","unstructured":"Sorli C.; Heile M.K.; Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc 2014,7,267-282","journal-title":"J Multidiscip Healthc"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/ejode.ejode_16_17","volume":"3","author":"Abbassy A.","year":"2017","unstructured":"Abbassy A.; Saad A.; Oraby A.; Effectiveness and safety of insulin glargine plus glimepiride after 6 months of treatment among patients with type 2 diabetes mellitus who failed premixed insulin: An observational study conducted in Egypt. Egyptian J Obesity, Diabetes Endocrinol 2017,3(2),75-82","journal-title":"Egyptian J Obesity, Diabetes Endocrinol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4158\/EP151126.CS","volume":"22","author":"Garber A.J.","year":"2016","unstructured":"Garber A.J.; Abrahamson M.J.; Barzilay J.I.; Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary. Endocr Pract 2016,22(1),84-113","journal-title":"Endocr Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pcd.2012.06.001","volume":"6","author":"Kostev K.","year":"2012","unstructured":"Kostev K.; Dippel F.W.; Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany. Prim Care Diabetes 2012,6(4),329-335","journal-title":"Prim Care Diabetes"},{"key":"ref=9","first-page":"34","volume":"8","author":"Kuritzky L.","year":"2006","unstructured":"Kuritzky L.; Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy. MedGenMed 2006,8(4),34","journal-title":"MedGenMed"},{"key":"ref=10","first-page":"100","volume":"17","author":"Edelman S.V.","year":"1999","unstructured":"Edelman S.V.;  A practical approach to combination therapy: Daytime oral agent(s) and bedtime NPH insulin, clinical diabetes 1999,17(3),100","journal-title":"A practical approach to combination therapy: Daytime oral agent(s) and bedtime NPH insulin, clinical diabetes"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","volume":"22","author":"Kalra S.","year":"2018","unstructured":"Kalra S.; Bahendeka S.; Sahay R.; Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus \u2013 International Task Force. Indian J Endocrinol Metab 2018,22(1),132-157","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4103\/ijem.IJEM_176_17","volume":"21","author":"Venkataraman S.","year":"2017","unstructured":"Venkataraman S.; Devarajan T.V.; Kandasamy N.; Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START Study. Indian J Endocrinol Metab 2017,21(5),745-750","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/VHRM.S33194","volume":"8","author":"Basit A.","year":"2012","unstructured":"Basit A.; Riaz M.; Fawwad A.; Glimepiride: evidence-based facts, trends, and observations. Vasc Health Risk Manag 2012,8,463-472","journal-title":"Vasc Health Risk Manag"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1185\/030079906X104786","volume":"22","author":"Umpierrez G.","year":"2006","unstructured":"Umpierrez G.; Issa M.; Vlajnic A.; Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006,22(4),751-759","journal-title":"Curr Med Res Opin"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.diabres.2015.05.025","volume":"109","author":"Mishriky B.M.","year":"2015","unstructured":"Mishriky B.M.; Cummings D.M.; Tanenberg R.J.; The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015,109(2),378-388","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=16","first-page":"30","volume":"S1","author":"Tripathi S.","year":"2019","unstructured":"Tripathi S.; Tiwaskar M.; Kota S.; Need of single pill fixed-dose combination with glimepiride in management of diabetes mellitus. J Assoc Physicians India 2019,S1,30-33","journal-title":"J Assoc Physicians India"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e10700","DOI":"10.7759\/cureus.10700","volume":"12","author":"Sahay R.K.","year":"2020","unstructured":"Sahay R.K.; Mittal V.; Gopal G.R.; Glimepiride and metformin combinations in diabetes comorbidities and complications: Real-world evidence. Cureus 2020,12(9),e10700","journal-title":"Cureus"},{"key":"ref=18","first-page":"25","volume":"59","author":"John M.","year":"2011","unstructured":"John M.; Basal insulin analogues-a review of recent data on efficacy and safety. J Assoc Physicians India 2011,59,25-28","journal-title":"J Assoc Physicians India"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","volume":"51","author":"Rosenstock J.","year":"2008","unstructured":"Rosenstock J.; Davies M.; Home P.D.; Larsen J.; Koenen C.; Schernthaner G.; A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008,51(3),408-416","journal-title":"Diabetologia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jdiacomp.2015.04.003","volume":"29","author":"Aschner P.","year":"2015","unstructured":"Aschner P.; Sethi B.; Gomez-Peralta F.; Insulin glargine compared with premixed insulin for management of insulin-na\u00efve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. J Diabetes Complications 2015,29(6),838-845","journal-title":"J Diabetes Complications"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1463-1326.2009.01165.x","volume":"12","author":"Fritsche A.","year":"2010","unstructured":"Fritsche A.; Larbig M.; Owens D.; H\u00e4ring H.U.; Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010,12(2),115-123","journal-title":"Diabetes Obes Metab"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1463-1326.2008.00873.x","volume":"10","author":"Davies M.","year":"2008","unstructured":"Davies M.; Lavalle-Gonz\u00e1lez F.; Storms F.; Gomis R.; Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the At.Lantus trial. Diabetes Obes Metab 2008,10(5),387-399","journal-title":"Diabetes Obes Metab"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13300-016-0153-3","volume":"7","author":"Hanefeld M.","year":"2016","unstructured":"Hanefeld M.; Monnier L.; Schnell O.; Owens D.; Early treatment with basal insulin glargine in people with type 2 diabetes: Lessons from ORIGIN and other cardiovascular trials. Diabetes Ther 2016,7(2),187-201","journal-title":"Diabetes Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4236\/jdm.2014.44039","volume":"4","author":"Kobayashi M.","year":"2014","unstructured":"Kobayashi M.; Tsukube S.; Ikeda Y.; Shuto Y.; Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 Study, a post-marketing surveillance for Lantus. J Diabetes Mellitus 2014,4(4),273-289","journal-title":"J Diabetes Mellitus"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/dom.14549","volume":"24","author":"Seufert J.","year":"2022","unstructured":"Seufert J.; Wiesli P.; Fritsche A.; Switching the basal insulin to insulin glargine 300 U\/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety. Diabetes Obes Metab 2022,24(1),72-81","journal-title":"Diabetes Obes Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.18865\/ed.27.1.45","volume":"27","author":"Echtay A.","year":"2017","unstructured":"Echtay A.; Andari E.; Atallah P.; Moufarrege R.; Nemr R.; Insulin detemir in combination with oral antidiabetic drugs improves glycemic control in persons with type 2 diabetes in near East countries: Results from the Lebanese subgroup. Ethn Dis 2017,27(1),45-54","journal-title":"Ethn Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"Ritzel R.","year":"2015","unstructured":"Ritzel R.; Roussel R.; Bolli G.B.; Patient\u2010level meta\u2010analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab 2015,17(9),859-867","journal-title":"Diabetes Obes Metab"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.2337\/dcS15-3011","volume":"39","author":"Standl E.","year":"2016","unstructured":"Standl E.; Owen D.R.; New long-acting basal insulins: Does benefit outweigh cost? Diabetes Care 2016,39(S2),S172-S179","journal-title":"Diabetes Care"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"41","author":"Rosenstock J.","year":"2018","unstructured":"Rosenstock J.; Cheng A.; Ritzel R.; More similarities than differences testing insulin glargine 300 units\/ml versus insulin degludec 100 units\/ml in insulin-naive type 2 diabetes: the randomized head-to-head bright trial. Diabetes Care 2018,41(10),2147-2154","journal-title":"Diabetes Care"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13340-015-0250-y","volume":"7","author":"Tsukube S.","year":"2016","unstructured":"Tsukube S.; Kadowaki T.; Odawara M.; Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. Diabetol Int 2016,7(3),299-307","journal-title":"Diabetol Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.diabres.2013.12.062","volume":"103","author":"Nyb\u00e4ck-Nakell \u00c5.","year":"2014","unstructured":"Nyb\u00e4ck-Nakell \u00c5.; Adamson U.; Lins P.E.; Landstedt-Hallin L.; Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years\u2019 duration-A randomised, double-blind, placebo-controlled, cross-over study. Diabetes Res Clin Pract 2014,103(2),286-291","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s13300-018-0413-5","volume":"9","author":"Blonde L.","year":"2018","unstructured":"Blonde L.; Meneghini L.; Peng X.V.; Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther 2018,9(3),1347-1358","journal-title":"Diabetes Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"107796","DOI":"10.1016\/j.diabres.2019.107796","volume":"155","author":"Yu H.M.","year":"2019","unstructured":"Yu H.M.; Kim S.J.; Chun S.W.; A comparison study on efficacy, insulin sensitivity and safety of Glimepiride\/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. Diabetes Res Clin Pract 2019,155,107796","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","volume":"361","author":"Holman R.R.","year":"2009","unstructured":"Holman R.R.; Farmer A.J.; Davies M.J.; Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009,361(18),1736-1747","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.diabres.2014.08.003","volume":"106","author":"Owens D.R.","year":"2014","unstructured":"Owens D.R.; Traylor L.; Dain M.P.; Landgraf W.; Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Res Clin Pract 2014,106(2),264-274","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e87799","DOI":"10.1371\/journal.pone.0087799","volume":"9","author":"Park C.Y.","year":"2014","unstructured":"Park C.Y.; Kang J.G.; Chon S.; Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One 2014,9(3),e87799","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1055\/s-2007-985367","volume":"116","author":"Schiel R.","year":"2008","unstructured":"Schiel R.; M\u00fcller U.; Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes 2008,116(1),58-64","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/j.1742-1241.2007.01598.x","volume":"61","author":"Hammer H.","year":"2007","unstructured":"Hammer H.; Klinge A.; Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007,61(12),2009-2018","journal-title":"Int J Clin Pract"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1758-5996-6-41","volume":"6","author":"Li C.J.","year":"2014","unstructured":"Li C.J.; Zhang J.Y.; Yu D.M.; Zhang Q.M.; Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr 2014,6(1),41","journal-title":"Diabetol Metab Syndr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1507\/endocrj.52.563","volume":"52","author":"Ose H.","year":"2005","unstructured":"Ose H.; Fukui M.; Kitagawa Y.; Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus. Endocr J 2005,52(5),563-569","journal-title":"Endocr J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/dom.12854","volume":"19","author":"Bonnet F.","year":"2017","unstructured":"Bonnet F.; Scheen A.; Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 2017,19(4),473-481","journal-title":"Diabetes Obes Metab"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1758-5996-5-6","volume":"5","author":"Rojas L.B.A.","year":"2013","unstructured":"Rojas L.B.A.; Gomes M.B.; Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013,5(1),6","journal-title":"Diabetol Metab Syndr"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc10-0017","volume":"33","author":"Pantalone K.M.","year":"2010","unstructured":"Pantalone K.M.; Kattan M.W.; Yu C.; The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010,33(6),1224-1229","journal-title":"Diabetes Care"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","volume":"138","author":"Fritsche A.","year":"2003","unstructured":"Fritsche A.; Schweitzer M.A.; Hring H-U.; Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003,138(12),952-959","journal-title":"Ann Intern Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.28.2.254","volume":"28","author":"Janka H.U.","year":"2005","unstructured":"Janka H.U.; Plewe G.; Riddle M.C.; Kliebe-Frisch C.; Schweitzer M.A.; Yki-J\u00e4rvinen H.; Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005,28(2),254-259","journal-title":"Diabetes Care"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ki.2014.19","volume":"87","author":"Lalau J.D.","year":"2015","unstructured":"Lalau J.D.; Arnouts P.; Sharif A.; De Broe M.E.; Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015,87(2),308-322","journal-title":"Kidney Int"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s13300-020-00925-8","volume":"11","author":"Cheng A.Y.Y.","year":"2020","unstructured":"Cheng A.Y.Y.; Wong J.; Freemantle N.; Acharya S.H.; Ekinci E.; The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review. Diabetes Ther 2020,11(11),2555-2593","journal-title":"Diabetes Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc18-0168","volume":"41","author":"Ritzel R.","year":"2018","unstructured":"Ritzel R.; Harris S.B.; Baron H.; A Randomized controlled trial comparing efficacy and safety of insulin glargine 300 units\/mL versus 100 units\/mL in older people with type 2 diabetes: Results from the SENIOR study. Diabetes Care 2018,41(8),1672-1680","journal-title":"Diabetes Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13300-018-0518-x","volume":"9","author":"Wiesli P.","year":"2018","unstructured":"Wiesli P.; Schories M.; Improved glycemic control with insulin glargine 300 U\/mL (Toujeo\u00ae) in patients with type 2 diabetes: Real-world effectiveness in Switzerland. Diabetes Ther 2018,9(6),2325-2334","journal-title":"Diabetes Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40266-013-0128-2","volume":"30","author":"Sorli C.","year":"2013","unstructured":"Sorli C.; Warren M.; Oyer D.; Mersebach H.; Johansen T.; Gough S.C.L.; Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging 2013,30(12),1009-1018","journal-title":"Drugs Aging"},{"key":"ref=51","year":"2016","unstructured":"Diabetes and Ramadan: practical guidance International Diabetes FederationAvailable at . Accessed on March 2022.2016","journal-title":"Diabetes and Ramadan: practical guidance"},{"key":"ref=52","year":"2021","unstructured":"Practical Guidelines Diabetes and RamadanAvailable at  Accessed on Jan 2023.2021","journal-title":"Practical Guidelines"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"108189","DOI":"10.1016\/j.diabres.2020.108189","volume":"166","author":"Hassanein M.","year":"2020","unstructured":"Hassanein M.; Buyukbese M.A.; Malek R.; Real-world safety and effectiveness of insulin glargine 300 U\/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract 2020,166,108189","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=54","first-page":"e6191","volume":"11","author":"Majumder A.","year":"2019","unstructured":"Majumder A.; RoyChaudhuri S; Sanyal D.; RoyChaudhuri S; Sanyal D.; A retrospective observational study of insulin glargine in type 2 diabetic patients with advanced chronic kidney disease. Cureus 2019,11(11),e6191","journal-title":"Cureus"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/dom.14043","volume":"22","author":"Haluz\u00edk M.","year":"2020","unstructured":"Haluz\u00edk M.; Cheng A.; M\u00fcller-Wieland D.; Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. Diabetes Obes Metab 2020,22(8),1369-1377","journal-title":"Diabetes Obes Metab"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"840","DOI":"10.5114\/aoms.2015.53304","volume":"4","author":"Sola D.","year":"2015","unstructured":"Sola D.; Rossi L.; Schianca G.P.C.; State of the art paper Sulfonylureas and their use in clinical practice. Arch Med Sci 2015,4(4),840-848","journal-title":"Arch Med Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4183\/aeb.2020.43","volume":"16","author":"Cerghizan A.","year":"2020","unstructured":"Cerghizan A.; Amorin P.; Catrinoiu D.; Creteanu G.; Adamescu E.; Moise M.; Efficacy and safety of basal insulin therapy in Romanian patients with type 2 diabetes in real-life settings: a sub-group analysis of dune study. Acta Endocrinol 2020,16(1),43-48","journal-title":"Acta Endocrinol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jdiacomp.2014.09.012","volume":"29","author":"Odawara M.","year":"2015","unstructured":"Odawara M.; Kadowaki T.; Naito Y.; Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus\u00ae to Oral Hypoglycemic Agents (ALOHA) study. J Diabetes Complications 2015,29(1),127-133","journal-title":"J Diabetes Complications"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4093\/dmj.2015.39.6.481","volume":"39","author":"Kim S.S.","year":"2015","unstructured":"Kim S.S.; Kim I.J.; Kim Y.K.; Insulin initiation in insulin-na\u00efve Korean type 2 diabetic patients inadequately controlled on oral antidiabetic drugs in real-world practice: The modality of insulin treatment evaluation study. Diabetes Metab J 2015,39(6),481-488","journal-title":"Diabetes Metab J"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3122\/jabfm.18.3.199","volume":"18","author":"Bethel M.A.","year":"2005","unstructured":"Bethel M.A.; Feinglos M.N.; Basal insulin therapy in type 2 diabetes. J Am Board Fam Med 2005,18(3),199-204","journal-title":"J Am Board Fam Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2337\/diacare.24.2.296","volume":"24","author":"Hermansen K.","year":"2001","unstructured":"Hermansen K.; Madsbad S.; Perrild H.; Kristensen A.; Axelsen M.; Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001,24(2),296-301","journal-title":"Diabetes Care"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"CMED.S9494","DOI":"10.4137\/CMED.S9494","volume":"5","author":"Nasrallah SN","year":"2012","unstructured":"Nasrallah SN; Reynolds LR; Insulin degludec, The new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes 2012,5,CMED.S9494","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref=63","first-page":"101","volume":"71","author":"Scheen A.J.","year":"2016","unstructured":"Scheen A.J.; Insuline glargine 300 U\/mL (Toujeo\u00ae). Rev Med Liege 2016,71(2),101-107","journal-title":"Rev Med Liege"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666230109104300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212444\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666230109104300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:41:38Z","timestamp":1694176898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212444\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399819666230109104300","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e090123212444"}}